Chart Industries, Inc. (NYSE: GTLS) — A Decided Equity: A High-Quality Cryogenics Compounder Wearing a $210 Cash Tag

Report date: 2026-06-21 Approach: Skeptical, evidence-driven, competitive-advantage lens Subject: Chart Industries, Inc. — NYSE: GTLS — Industrials / Process & Cryogenic Equipment (energy & industrial gas)

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice. The analysis that follows (Sections 1–15) deliberately carries no recommendation and no price target; it discusses valuation only as embedded expectations and scenarios.

Call: HOLD / no fundamental edge here — the equity is decided. As a merger-arb instrument: a thin-spread, late-stage, high-probability cash deal (defensible “fair value” zone $208–$210, i.e., essentially the $210 deal price less a small completion/timing haircut). For a fundamental long-only investor there is nothing left to do: the upside is ~$2 (≈1%), the business’s fate is sealed by contract, and the only real variable is a low-probability deal break. Not a short.

Chart Industries is, on the merits, a genuinely good business that got much better after the 2023 Howden acquisition — a four-segment cryogenic and process-equipment franchise with two ~30%±margin crown jewels (Repair, Service & Leasing and Heat Transfer Systems), a 1.33 book-to-bill, a $5.9B backlog, and real exposure to LNG, industrial gas, and the data-center cooling build. In a vacuum I’d want to own this kind of compounder on weakness. But it is no longer trading on its fundamentals. On 29 July 2025 Baker Hughes agreed to buy the whole company for $210.00/share in cash ($13.6B enterprise value), topping a poorly-received all-stock merger-of-equals with Flowserve that Chart had announced seven weeks earlier. Shareholders approved; the U.S. HSR period expired in November 2025; China’s SAMR granted unconditional clearance in late November 2025; only the EU Phase I review (filed May 2026) remains, with management guiding to a Q2-2026 close. The stock now sits at $207.99 — a ~0.97% gross spread to the cash price.

That spread is the entire investable proposition, and it is a classic late-stage arb: small, positive carry (~1% over a few weeks-to-months = a healthy annualized rate if it closes on schedule) against a fat-tailed downside. If the deal somehow broke, GTLS would not hold $208 — it would fall back toward its pre-deal standalone range of roughly $145–$175 (it traded $144–$171 in 2025, and the Flowserve all-stock deal knocked it to $146), a ~20–30% drawdown. The market is pricing deal-completion probability in the high-90s%, and I think that’s about right: two of three major jurisdictions cleared with no remedies, Baker Hughes/Chart product overlap is minimal (oilfield-and-energy-tech buyer, cryo-equipment target), and Baker Hughes posted a $500M reverse termination fee — a credible signal it expects to close. Framing: this is a special situation / merger-arb, not a momentum name and emphatically not a falling knife — the FactorsToday tape proves it, with six-month realized volatility collapsed to ~2.3% and max drawdown of just −0.9% as the stock pins to the cash price. Conviction: high on the characterization (it’s a near-closed cash deal), medium on residual deal-break risk. The single fact that flips me bullish (as an arb): EU clearance / definitive close — at which point the trade simply pays the last dollar and ends. The single fact that flips me bearish: an unexpected EU Phase II opening, a financing wobble at Baker Hughes, or a regulatory remedy demand — any of which would blow the spread out and re-expose the standalone ~$145–175 value.

One-line tag: “The analysis is over; the deal isn’t quite. Clip the last dollar or move on.”

📈 Stock Price Action — Five-Year Event Map

Chart’s five-year chart is a violent clean-energy boom-bust, a debt-financed transformation, and finally a takeover that froze the stock in place. From a COVID low near $17 (Mar-2020), GTLS rode the hydrogen/LNG/decarbonization mania to a ~$239 peak in 2022, gave most of it back as rates rose and it levered up for the $4.4B Howden acquisition (closed Mar-2023, stock ~$109), recovered to ~$190 by end-2024 on margin expansion and backlog, then was bid away — first by Flowserve (all-stock, poorly received), then decisively by Baker Hughes (all-cash, $210). It now trades at $207.99 (18-Jun-2026), ~1% below the cash deal price, in a 52-week range of roughly $115–$218, with realized volatility near zero. The price today is a contract term, not a market opinion.

Cycle narrative. (1–2) Chart was a poster child of the 2020–22 energy-transition trade, with a stock that quadrupled-plus on hydrogen and LNG enthusiasm before peaking near $239. (3) The defining corporate event of the era was the transformational, debt-heavy Howden acquisition — it doubled revenue and re-shaped the margin profile, but the leverage and a 2022–23 rate shock cut the stock in half to ~$109. (4) From there the equity worked: integration delivered, gross margin pushed above 33%, backlog hit records, and the multiple recovered toward $190. (5) A 2025 order-timing/industrial-gas air-pocket pulled it back to ~$161. (6) On 4-Jun-2025 the Flowserve all-stock “merger of equals” landed badly — Chart fell 9.5% on heavy volume, the market reading it as Chart accepting equity at a low valuation. (7) Seven weeks later, on 29-Jul-2025, Baker Hughes pre-empted with an all-cash $210 offer; Chart terminated the Flowserve agreement and the stock jumped ~16% to ~$199 on ~21M shares. (8) Since then it has done what cash-deal targets do — ground slowly from ~$199 toward the $210 par as each regulatory gate cleared, with volatility collapsing to a flat line. Every move on this chart is now in the past tense.

1. Executive Summary

Chart Industries is a global designer and manufacturer of highly engineered cryogenic and process equipment for the energy and industrial-gas value chains, organized into four segments: Repair, Service & Leasing (FY25 sales $1,303.7M, 32.6% adj. operating margin), Heat Transfer Systems ($1,237.7M, 30.1%), Specialty Products ($1,098.4M, 15.4%), and Cryo Tank Solutions ($624.2M, 12.8%). FY2025 revenue was $4,264.0M, adjusted EBITDA roughly $905.7M (21.2% margin), adjusted diluted EPS $9.72, free cash flow $204.8M, with a $5,886.2M backlog and a 1.33 book-to-bill — order momentum, not order decline. The business was transformed by the $4.4B Howden acquisition (closed March 2023), which roughly doubled revenue, lifted the recurring-aftermarket and high-margin heat-transfer mix, and loaded the balance sheet with debt and intangibles (net leverage ended FY25 at 2.83x; tangible book equity is deeply negative on ~$3.07B goodwill and ~$2.5B other intangibles).

But none of that is the investment question today. On 29 July 2025, Baker Hughes agreed to acquire Chart for $210.00 per share in cash — a $13.6B enterprise-value transaction that topped a previously announced all-stock merger-of-equals with Flowserve. The deal has cleared the most consequential gates: Chart shareholders approved it; the U.S. HSR waiting period expired (6 Nov 2025); China’s SAMR granted unconditional clearance (late Nov 2025). The remaining condition is EU antitrust (Form CO filed 21 May 2026, Phase I), with management guiding to a Q2-2026 close and an outside date of 28 July 2026 that auto-extends in two six-month steps (to 28 July 2027) if only regulatory approvals remain. Termination fees are $250M (Chart → Baker Hughes) and a credibility-signaling $500M reverse fee (Baker Hughes → Chart).

At $207.99, GTLS trades at a ~0.97% gross spread to the cash price. The equity’s return is therefore almost entirely a function of (a) whether and when the deal closes, and (b) the standalone value the stock would revert to if it broke. We assess deal-completion probability as high (complementary businesses, two of three jurisdictions cleared with no remedies, a large reverse break fee). The standalone break-value anchor is ~$145–$175 (its 2025 pre-deal trading range), implying ~20–30% downside in the low-probability break scenario against ~1% upside to par. This memo covers the business on its merits — because break risk makes standalone value relevant — but the reader should hold one fact foremost: this is a decided equity wearing a cash tag. No price target and no recommendation appear below; the only opinion in this document is the labeled Claude’s Take above.

2. Business Overview

Chart Industries is a ~167-year-old company (founded 1859, Ball Ground, Georgia; NYSE-listed since 2006) that engineers, manufactures, and services equipment used to liquefy, store, transport, vaporize, and apply gases and liquids — the physical infrastructure of the industrial-gas and energy-molecule economy. Its products handle cryogenic temperatures (down to ~−196 °C for liquid nitrogen, lower still for liquid hydrogen and helium), which is a demanding engineering domain with meaningful safety, metallurgy, and process know-how. The company describes its franchise as spanning “molecule” markets: LNG, industrial gases (oxygen, nitrogen, argon, CO₂), hydrogen, helium, and increasingly carbon capture, water treatment, food & beverage, space, and data-center cooling.

Post-Howden, Chart reports four segments (FY2025 sales / adjusted operating margin):

• Repair, Service & Leasing (RSL) — $1,303.7M (30.6% of revenue) / 32.6% margin. The aftermarket: installed-base service, spare parts, repairs, plant services for brazed-aluminum heat exchangers and cold boxes, equipment leasing, and digital monitoring (“Uptime”). This is the highest-quality revenue in the company — recurring, high-margin, capital-light, and tied to a large installed base (assets under management/service agreements grew 21% in 2025; Uptime connections +29%). It is the segment that most resembles a moat.
• Heat Transfer Systems (HTS) — $1,237.7M (29.0%) / 30.1% margin. Process technology and large engineered equipment for LNG (liquefaction trains, cold boxes, brazed-aluminum heat exchangers), petrochemicals, and — increasingly — data-center cooling. Project-driven and lumpy (Q4-2025 HTS orders fell 61% YoY on order timing) but high-margin and backlog-rich.
• Specialty Products — $1,098.4M (25.8%) / 15.4% margin. The “new molecules” growth bucket: hydrogen equipment, CO₂ capture, biogas, water treatment, food & beverage, space/aerospace, and other niche cryogenic applications. Lower margin (earlier-stage, more competitive) but the segment carrying the energy-transition optionality.
• Cryo Tank Solutions (CTS) — $624.2M (14.6%) / 12.8% margin. The legacy core: bulk and packaged cryogenic storage tanks, trailers, ISO containers, and microbulk units for industrial gas and LNG “virtual pipeline” distribution. The most commoditized, most cyclical (tied to industrial-gas demand; FY25 sales −2.1%), and lowest-margin segment.

The revenue model blends lumpy project/equipment sales (HTS, CTS, much of Specialty) with a growing recurring aftermarket annuity (RSL plus service attach across the installed base). Roughly a third of revenue (RSL) is recurring/aftermarket; the rest is order-book-driven. Book-to-bill of 1.33 and a $5.9B backlog mean the near-term revenue trajectory is largely visible and rising — 44% of the year-end backlog is expected to convert within twelve months. Geographically the business is global, with manufacturing and service footprints across North America, Europe, and Asia.

Verdict: A real, diversified, engineering-intensive industrial franchise with a high-quality recurring aftermarket and two ~30%-margin segments, balanced by a commoditized, cyclical tank business and an earlier-stage Specialty bucket. On the merits it is a good — not exceptional — industrial compounder. For the purposes of this report, the business overview matters mainly as the break-scenario substrate: this is what an owner would be left holding if the Baker Hughes deal failed.

3. Industry Dynamics

Chart sits in the engineered industrial- and energy-equipment value chain — supplying capital goods and aftermarket services to industrial-gas majors (Linde, Air Products, Air Liquide), LNG developers and EPC contractors, energy and petrochemical operators, and a long tail of specialty end-markets. The structural attractiveness varies sharply by segment, which is exactly why the four-segment mix matters.

Demand drivers are secular-plus-cyclical. The bullish structural case rests on three molecule tailwinds: (1) LNG capacity build — a multi-year global wave of liquefaction and regasification investment for which Chart supplies process technology and cold-boxes; (2) industrial-gas growth tied to electronics, healthcare, and manufacturing; and (3) energy transition — hydrogen, carbon capture, and biogas, where Chart has positioned its Specialty segment. A newer, genuinely incremental driver is data-center cooling, where Chart’s heat-transfer and process expertise is finding demand as AI compute strains thermal systems. Against these sit real cyclicality: industrial-gas tank demand tracks industrial production, LNG and petrochemical orders are lumpy and tied to final-investment-decision (FID) cycles, and Specialty’s hydrogen/CCUS markets remain policy-dependent and have repeatedly disappointed on timing.

Competitive structure is fragmented and segment-specific. Chart competes against a varied set: in cryogenic tanks and components, against regional fabricators and players like INOX India, Cryofab, and the in-house capabilities of gas majors; in heat transfer / brazed-aluminum exchangers and cold boxes, against Linde Engineering, Air Products, and a small set of specialist exchanger makers; in process technology, against EPC and licensor competition; in Specialty, against a crowded field of hydrogen and CCUS equipment entrants. There is no single dominant competitor Chart faces across the board, and in several niches Chart is itself the scale leader. Barriers to entry are moderate and engineering-based — cryogenic metallurgy, safety qualification, reference installations, and aftermarket installed base — rather than structural monopoly.

Capital-cycle read (Marathon lens). The energy-transition equipment space attracted heavy capital and enthusiasm in 2020–22 (Chart’s own stock quadrupled), which historically presages mean-reverting returns. But the core cryogenic/industrial-gas equipment niche is more rationally supplied than the hype-driven hydrogen tail, and Chart’s aftermarket annuity dampens the cyclicality of the equipment book. The Howden deal consolidated the heat-transfer/aftermarket niche, improving Chart’s structural position. Where the cycle is most dangerous is Specialty (hydrogen/CCUS), where overcapacity and policy disappointment remain live risks.

Verdict: A structurally average-to-good industry with strong secular demand narratives (LNG, industrial gas, data-center cooling) offset by genuine cyclicality, FID-timing lumpiness, fragmented competition, and a policy-dependent transition tail. The aftermarket and heat-transfer niches are the structurally attractive parts; tanks and Specialty are more contested. This is a good industry to be the scale aftermarket player in, and a tougher one to be a commodity-tank fabricator in.

4. Competitive Position

The honest competitive read on Chart is that it has pockets of genuine advantage rather than one wide moat. Using Greenwald’s taxonomy:

• Customer captivity / switching costs (the strongest, in RSL and HTS). Once Chart’s brazed-aluminum heat exchangers, cold boxes, and cryogenic systems are installed in an LNG train, air-separation unit, or industrial-gas plant, the aftermarket is sticky: the OEM that built the equipment is the natural servicer, spare-parts supplier, and upgrade vendor, and switching to a third party carries qualification, warranty, and downtime risk. The 32.6%-margin RSL segment and the 21% growth in assets-under-service are the financial fingerprint of that captivity. This is a real, if narrow, moat — it would deteriorate if Chart lost the installed base, which it will not quickly.
• Intangibles / engineering know-how and references (moderate). Cryogenic engineering is hard; safety qualification and reference installations create credibility barriers, especially in large LNG and high-purity applications. This supports the HTS franchise’s 30%+ margins. It is defensible but not unique — Linde Engineering and Air Products have comparable or greater capability in adjacent niches.
• Economies of scale (moderate, post-Howden). The Howden combination gave Chart greater scale in heat transfer and aftermarket, and a broader “full molecule” product breadth that lets it cross-sell across a project. Scale in a fragmented niche is a genuine if modest edge.
• Cost advantage / brand (weak). In Cryo Tank Solutions, Chart competes largely on price, lead-time, and reach against regional fabricators; there is little durable advantage, and margins (12.8%) reflect it. In Specialty, the brand is one of many in an early, crowded field.

Direct comparison. Against the gas majors’ in-house engineering (Linde, Air Products, Air Liquide), Chart is the independent “arms dealer” — it can sell to all of them and to merchant/LNG customers, which is both a strength (neutral supplier, broad addressable market) and a vulnerability (its largest potential customers are also potential competitors who can in-source). Against pure fabricators, Chart wins on breadth, engineering, and aftermarket. Against the new hydrogen/CCUS entrants, Chart has scale and a balance sheet but no decisive technology lock.

ROIC test. The most damning evidence against a wide moat is the return profile: post-Howden ROIC has run ~6–7% (FY24 7.2%, FY23 6.3%) — at or below a reasonable WACC for a levered industrial. That is the arithmetic of a company that paid up for Howden (loading $3B+ of goodwill) and is still earning into the purchase price. The underlying segments earn attractive margins, but the capital deployed to assemble them has not yet cleared its cost. A company with a wide, durable moat would show ROIC comfortably above WACC; Chart does not, yet.

Verdict: A narrow, segment-specific moat — real customer captivity and engineering intangibles in the aftermarket and heat-transfer franchises, weak-to-absent advantage in tanks and Specialty — sitting atop a balance sheet whose returns on total invested capital are still only around WACC. This is “good business, average returns-on-capital, assembled expensively.” It explains both why Chart was an attractive acquisition target (high-quality cash-flow streams, consolidation logic, synergies) and why a standalone equity holder should be sober about the absence of a fortress.

5. Growth History and Forward Opportunities

History is a story of one giant acquisition bracketed by organic cyclicality. Revenue trajectory: $1,177M (2020) → $1,318M (2021) → $1,612M (2022) → $3,353M (2023) → $4,160M (2024) → $4,264M (2025). The step-change between 2022 and 2023 is almost entirely the Howden acquisition (closed March 2023), which roughly doubled the company. Organic growth on the enlarged base has been mid-single-digit and choppy: FY25 revenue rose only 2.5% as industrial-gas/CTS softness (−2.1%) and HTS order-timing offset growth elsewhere. So the “growth history” is really (a) a transformational M&A leap, plus (b) modest, cyclical organic growth, plus © substantial margin expansion — gross margin climbed from ~25% (2022) to ~33.7% (2025), and adjusted EBITDA margin from ~14.5% to ~21.2%, as the Howden mix (aftermarket, heat transfer) and synergies flowed through. The eleven-consecutive-quarters-above-30%-gross-margin streak is the real achievement of the post-Howden era.

Forward opportunities (relevant to standalone/break value, and to why Baker Hughes wanted it):

• Backlog visibility. A $5,886M backlog and 1.33 book-to-bill mean orders are outrunning shipments; near-term revenue is well-supported, with 44% of backlog converting within a year. This is the single best evidence that the business (as opposed to the stock) has forward momentum.
• LNG. A continued global liquefaction build supports HTS process-technology and cold-box demand.
• Data-center cooling. A genuinely new vector — Chart explicitly cited converting “LNG and data center backlog to sales” in HTS. This is the most exciting incremental TAM and a key part of Baker Hughes’ stated rationale (data centers, new energy).
• Aftermarket compounding. RSL grows as the installed base grows; 21% growth in assets under service is a durable, high-margin annuity that should keep compounding regardless of the equipment cycle.
• Specialty/transition optionality. Hydrogen, CCUS, biogas, space, water — real option value, but policy-dependent and historically slow to convert.

Quality of growth. Mixed. The margin improvement is high-quality and durable (mix + synergies). The revenue growth has been bought, not organically generated — Howden was a $4.4B acquisition, and organic growth is cyclical mid-single-digit. The most attractive forward drivers (aftermarket annuity, data-center cooling, LNG) are real; the Specialty transition story is lower-quality and lumpier. Net: a business with visible near-term growth (backlog) and durable margins, but a modest organic growth engine that required expensive M&A to scale.

Verdict: Medium-quality growth — excellent margin progression and strong backlog visibility, offset by an organic growth rate that is merely cyclical mid-single-digit and a transformation that was acquired at a high price. Good enough to make Chart a desirable target; not so explosive as to make $210 cash an obvious giveaway.

6. Financial Quality

Income statement. FY2025: revenue $4,264.0M; gross margin 33.7%; adjusted EBITDA ~$905.7M (21.2%); GAAP operating income $624.4M (14.6% operating margin). The headline that matters for quality-of-earnings is the chasm between GAAP and adjusted EPS: reported diluted EPS of $0.30 versus adjusted diluted EPS of $9.72. That gap is mostly real economic items that GAAP includes and “adjusted” strips: (a) heavy interest expense (~$292M on the Howden debt), (b) large intangible amortization from the Howden purchase accounting, and © mark-to-market and non-operating noise — FY25 carried ~$311.6M of “other non-operating income” plus mandatory-convertible preferred dividends (~$27.2M) that depress earnings-to-common. The truth lies between the two figures: GAAP $0.30 understates true cash earning power (it’s burdened by non-cash amortization and one-time marks), while adjusted $9.72 flatters it (it adds back real, recurring interest-adjacent costs of the capital structure). A defensible owner-earnings figure sits well below $9.72 once you charge the real interest and maintenance reality but well above $0.30.

Cash flow. This is the more sobering lens. FY2025 operating cash flow was only $292.7M (down from $503M in FY24) on a large working-capital build (receivables/contract assets −$221.6M as backlog converts), and free cash flow was $204.8M — i.e., FCF/adjusted-net-income conversion is poor (adjusted EPS $9.72 × ~45M shares ≈ ~$440M of “adjusted earnings” against ~$205M FCF). Some of that is timing (working capital tied up in a rising backlog), but it underscores that the adjusted earnings are not fully cash-backed, and that this is a working-capital-intensive, project-heavy business. FY24’s $503M OCF / ~$375M FCF (after ~$128M capex) was a better year; the two-year average is more representative than either.

Balance sheet. The defining feature is leverage and intangibles from Howden. Net debt ~$3.2B against adjusted EBITDA ~$905.7M = ~3.5x gross / 2.83x net leverage (management basis) at year-end 2025 — elevated but declining (from ~3.6–3.7x net debt in 2023–24) and serviceable given the cash generation. The asset side is dominated by $3.07B goodwill + ~$2.5B other intangibles, so tangible book equity is deeply negative (~−$49/share) — an accounting artifact of an all-but-all-intangible acquisition, not a solvency signal, but a reminder that book value here is meaningless. Current ratio ~1.36; liquidity adequate. There is a mandatory convertible preferred in the capital structure (the source of the ~$27.2M preferred dividend), which is why earnings-to-common diverges from net income.

Returns. ROIC ~6–7%, ROE distorted by the thin/negative tangible equity. Margins improve with scale and mix (the post-Howden gross-margin expansion is the proof), but returns on the capital actually deployed are only around WACC — the central financial-quality caveat.

Verdict: Economics that improve with scale at the margin line but not (yet) at the capital line. High and rising segment margins, a strong backlog, and deleveraging are genuine positives; poor FCF conversion, heavy leverage, deeply negative tangible book, a complex capital structure, and a GAAP-to-adjusted gap that requires care are genuine cautions. This is a good operating business with an expensively-financed, intangible-heavy balance sheet — precisely the profile a well-capitalized strategic acquirer (Baker Hughes) can improve by refinancing the debt cheaply and extracting synergies.

7. Capital Allocation

Chart’s capital-allocation record over the last cycle is dominated by one enormous, defining decision: the $4.4B Howden acquisition (announced November 2022, closed March 2023), funded with a mix of debt, a mandatory-convertible preferred, and equity. The verdict on Howden is genuinely two-sided. For: it transformed Chart’s mix toward high-margin aftermarket and heat transfer, roughly doubled revenue, drove gross margin from ~25% to ~34%, and ultimately made Chart attractive enough to be acquired at $210 — value was, in the end, realized for shareholders. Against: it was expensive (loading $3B+ of goodwill), it pushed leverage to ~3.6x+, it produced ROIC of only ~6–7% (the company is still earning into the price it paid), and it left a complex capital structure with negative tangible equity and a preferred overhang. A disciplined-value scorecard would call Howden “strategically sound, financially aggressive, and bought at a full price” — the kind of deal that works if integration and synergies deliver (they largely have, on margin) but that destroyed the balance sheet’s simplicity and depressed returns on capital for years.

Beyond Howden, capital allocation has been about deleveraging (net debt down from ~$3.65B in 2023 to ~$3.2B in 2025) and a small dividend (~$0.60/share, ~$27M/year — really the preferred coupon; the common pays little). There have been no meaningful buybacks in the post-Howden period (the balance sheet couldn’t support them), and the equity count drifted up with the Howden financing and convertibles rather than down. R&D and growth capex have been directed at Specialty (hydrogen/CCUS), data-center cooling, and aftermarket digital (“Uptime”) — reasonable, growth-oriented internal allocation.

The final capital-allocation act — selling the company — is the most important and, in hindsight, shareholder-friendly. Management first agreed an all-stock merger-of-equals with Flowserve (June 2025) that the market openly disliked (the stock fell 9.5% on the announcement, reading it as Chart accepting underpriced equity). When Baker Hughes pre-empted with a superior all-cash $210 offer (July 2025), Chart’s board terminated the Flowserve deal (paying a break fee) and accepted cash — the correct decision, crystallizing a certain $210 over an uncertain all-stock combination. That the board was willing to switch from a friendly MOE to a higher cash bid, rather than entrenching, is a positive governance signal.

Incentives. As a near-closed-deal target, current incentive design is largely moot (management will be cashed out / change-of-control vested). Historically, Chart’s compensation has been a fairly standard industrial mix; the absence of a strong returns-on-capital metric is a generic demerit, but the realized outcome — a clean cash exit at $210 after a transformational deal — is the result shareholders ultimately care about.

Verdict: Aggressive but ultimately value-realizing. The Howden deal was strategically right and financially stretched, leaving low returns on capital; the decision to sell — and specifically to switch from the poorly-received Flowserve stock deal to Baker Hughes’ superior cash bid — was the right capital-allocation call and is the proximate reason GTLS holders are looking at $210 in cash rather than Flowserve paper.

8. Changes and Headwinds — Last Two Years

The last two years are the story, and they are almost entirely corporate-event driven:

• Howden integration and margin expansion (2023–2025). The defining operational achievement: gross margin pushed above 30% for eleven straight quarters and above 33% for seven, adjusted EBITDA margin to ~21%, net leverage down to 2.83x. The integration largely worked.
• 2025 order/industrial-gas wobble. Early 2025 saw the stock derate to ~$144–$161 on industrial-gas softness (CTS −2.1%) and lumpy HTS order timing (Q4-25 HTS orders −61% YoY) — a reminder of the cyclicality beneath the secular narrative. Backlog (1.33 book-to-bill) nonetheless stayed strong.
• Flowserve merger-of-equals — announced 4 June 2025, terminated. An all-stock combination poorly received by Chart holders (−9.5% on the day). Superseded seven weeks later.
• Baker Hughes acquisition — announced 29 July 2025 (THE change). $210/share all cash, $13.6B EV, ~$325M targeted synergies. Chart terminated Flowserve to accept it. Stock +15.8% to ~$199.
• Regulatory clearances (the de-risking sequence). Shareholder approval; HSR period expired 6 Nov 2025; China SAMR unconditional clearance late Nov 2025; EU Form CO filed 21 May 2026 (Phase I). Two of three major jurisdictions cleared with no remedies.
• Management transition. Long-time CEO Jill Evanko’s tenure gave way during the deal period (ROIC profile lists Gerald F. Vinci); in a pending-acquisition context, leadership questions are subordinate to deal closure.

Headwinds (all now secondary to the deal): residual EU antitrust review; the small risk of a financing or remedy hiccup; underlying cyclicality (industrial gas, FID timing) that would matter in a break scenario; the hydrogen/CCUS transition’s chronic timing disappointments; and elevated leverage that would constrain a standalone Chart.

Verdict: The changes of the last two years strengthened the realized outcome for shareholders — a high-quality business, expensively assembled and operationally improved, was sold for cash at a premium after a competitive process. The thesis is no longer about the business; it is about getting the last dollar of a deal that has already cleared its hardest gates.

9. Risk Analysis (Risk Matrix)

For a near-closed all-cash target, the risk profile inverts from a normal equity: operational/competitive risks recede; deal-completion and timing risks dominate. The asymmetry is the whole story — ~1% upside to par vs ~20–30% downside on a break.

Catastrophic-loss assessment: For a holder at $208, a “total loss” is implausible; the realistic bad case is a deal break sending the stock to ~$145–175 (a ~20–30% drawdown), partially cushioned over time by the $500M reverse break fee accruing to Chart and the underlying ~$200M+ FCF business. The probability-weighted risk is small but the shape is unattractive for a fresh buyer: you are picking up pennies (1%) in front of a low-probability ~25% air-pocket.

10. Valuation Discussion (Embedded Expectations)

The price is not a valuation; it is a contract term. At $207.99 against a $210.00 cash offer, the market is not expressing a view on Chart’s intrinsic value — it is discounting the cash price by ~1% for the residual probability and time-value of non-completion. The embedded-expectations question is therefore not “what must be true to justify the multiple?” but “what completion probability and timeline is the spread pricing, and is that fair?”

Arb math. Gross spread = $210.00 − $207.99 = $2.01, or ~0.97%. With a Q2/July-2026 expected close (weeks-to-a-few-months from the 21-June report date) and an outside date of 28 July 2026, a ~1% gross return over, say, 1–2 months annualizes to a high-single-digit to mid-teens % rate — an ordinary, healthy late-stage-arb return, consistent with the market assigning a high-90s% completion probability. A simple two-outcome decomposition: if P(close)=97% at $210 and P(break)=3% at a ~$160 standalone midpoint, expected value ≈ 0.97×$210 + 0.03×$160 ≈ $208.5 — almost exactly where the stock trades. The spread is fairly priced: it neither screams free money nor flashes distress.

What the deal price itself implies about value. Baker Hughes is paying ~21.6x FY25 adjusted diluted EPS ($9.72) and ~15x FY25 adjusted EBITDA (~$905.7M) for a $13.6B EV — a full strategic multiple for a mid-single-digit organic grower with ~6–7% ROIC, justified (from BKR’s seat) by ~$325M of synergies, the high-margin aftermarket annuity, LNG/data-center exposure, and the strategic fit with Baker Hughes’ industrial-energy-technology portfolio. On Chart’s own AZI own-history percentiles, the price sits at the 68th composite percentile (P/B 73rd, P/S 64th) — but those are now meaningless, set by the arb rather than the market.

Standalone / break-value anchor (the relevant downside). Strip the deal and value Chart on fundamentals: pre-announcement it traded $144–$171 in 2025, and the Flowserve all-stock deal (a market-clearing reference for “what is Chart worth without a cash bid?”) implied ~$146. A standalone DCF/multiple frame — ~$905M EBITDA, ~$205M FCF, ~3.5x leverage, mid-single-digit growth, high-but-not-fortress margins — supports a ~$145–$175 standalone equity zone (call it ~9–11x EBITDA / ~15–18x adjusted EPS, net of leverage), below the $210 cash price. That gap (≈$35–65/share, or ~20–30%) is the premium Baker Hughes is paying and the downside an owner is exposed to if the deal breaks.

Scenario summary (embedded-expectations frame, not a target):

• Bull (deal closes on schedule, ~97% weighted): holder receives $210 cash in Q2/Q3 2026; total return from $208 ≈ +1% (plus the annualized carry of a short hold).
• Base (closes with modest slippage): $210 later in 2026 under the auto-extending outside date; lower annualized return, same nominal.
• Bear (deal breaks, ~3% weighted): stock reverts to ~$145–$175 standalone; −20% to −30%, cushioned over time by the $500M reverse break fee and the underlying FCF business.

Verdict: GTLS is fairly priced as a late-stage cash-merger arb — the ~1% spread reasonably compensates for a small, fat-tailed completion risk. There is no fundamental valuation edge for a long-only investor: the equity offers ~1% of upside, with its real intrinsic-value range (~$145–$175 standalone) far below the trading price and relevant only if the deal fails. No price target is expressed; the figures above are scenario anchors, not recommendations.

11. Variant Perception

Consensus belief. The market consensus is straightforward and, in our view, basically correct: the Baker Hughes acquisition will close in 2026 at $210 in cash, and GTLS is now a low-risk, low-return arbitrage instrument. The ~1% spread, the collapsed volatility (6-month realized ~2.3%, max drawdown −0.9%), and the steady grind from $199 toward $210 all encode a high-completion-probability consensus.

Strongest bull case (for the arb). The deal is more certain than even a 1% spread implies. The two hardest antitrust jurisdictions — the U.S. (HSR) and China (SAMR, which granted unconditional clearance and has been the graveyard of several U.S.–U.S. and U.S.–EU deals) — are already cleared with no remedies. The businesses are genuinely complementary (oilfield-and-energy-tech acquirer, cryogenic-equipment target) with minimal horizontal overlap, making an EU Phase II opening unlikely. Baker Hughes posted a $500M reverse break fee and has already raised euro debt to fund the deal — strong “we will close” signals. On this view the residual risk is timing, not completion, and the spread is if anything slightly too wide.

Strongest bear case. EU antitrust is the one gate that can still bite. Brussels has shown willingness to scrutinize energy/industrial deals and to demand remedies even where overlap looks modest; a Phase II opening would push the close into late 2026/2027 (the outside date auto-extends to July 2027 precisely to accommodate this), crushing the annualized return and re-introducing genuine break risk. Layer on a small but non-zero chance of a financing or MAC complication, and the bear argues the ~1% spread underprices the left tail — you are not paid enough for a possible −25% reversion to ~$160.

The 3–5 assumptions that matter most:

1. EU Phase I clears without remedies (the swing factor). Falsified by: a Phase II opening or remedy demand announced after the May-2026 filing.
2. Baker Hughes remains committed and able to fund. Falsified by: any BKR financing wobble, strategic reversal, or attempt to renegotiate terms.
3. No MAC event at Chart (a demand collapse or fundamental deterioration severe enough to trigger the material-adverse-change clause). Falsified by: a catastrophic order/cancellation shock — low probability given the $5.9B backlog.
4. Standalone break value is ~$145–$175 (defines the downside if 1–3 fail). Falsified by: evidence the underlying business has materially re-rated up or down since the deal.
5. No competing/improved bid (caps upside at $210). Already effectively settled by the Flowserve→BKR competitive process.

Where consensus could be offsides. The factor/positioning tape (FactorsToday) is unusually clean here: the stock has decoupled from the market (trailing beta is a backward-looking ~1.5 artifact; realized volatility has gone to a flat line as it pins to cash). This is the textbook signature of a deal that the market believes will close — and the related-stocks model can’t even find industrial peers anymore, matching GTLS to low-vol/momentum ETF baskets because its return stream is now “carry,” not “equity.” The variant view, if any, is not about Chart’s fundamentals (which no longer drive the price) but about EU antitrust handicapping — and there the complementary-business fact pattern and the unconditional China/HSR clearances argue the bulls have it right. Our read: consensus is approximately correct; the marginal edge, if it exists, is a slightly-too-wide spread for arb desks, not a fundamental opportunity for long-only capital.

12. Fact vs. Interpretation Table

13. Open Questions

1. EU timing and depth — Will the May-2026 Phase I filing clear unconditionally and on the Q2/July timeline, or could the Commission open Phase II or seek remedies? (The single most important open question.)
2. Exact ticking/economics — Does the merger agreement carry any ticking fee or dividend mechanics that change the effective return as the close slips? (DEFM14A detail not fully captured.)
3. Standalone EPS power normalized — What is Chart’s true through-cycle owner-earnings (charging real interest and maintenance), bridging the $0.30 GAAP / $9.72 adjusted gap? Relevant only in a break scenario.
4. Synergy realism — Are Baker Hughes’ $325M synergies credible, and do they imply the $210 price already captures value an independent Chart could not? (Affects whether $210 was “full” or “generous.”)
5. Working-capital normalization — How much of the weak FY25 FCF conversion is backlog-driven timing that reverses, versus a structurally working-capital-hungry model?
6. Flowserve break fee paid — The exact fee Chart paid to terminate the Flowserve MOE (a small drag, already history).
7. Other jurisdiction approvals — Any non-EU/non-US/non-China filings still outstanding that could gate the close.

14. What Must Be True (Bull and Bear, with Falsification Tests)

For the deal to complete at $210 (the “bull”/base case):

• EU antitrust clears (Phase I, or Phase II with acceptable/no remedies) before the auto-extended outside date.
• Baker Hughes remains willing and able to fund and close (no financing failure, no strategic reversal, no successful renegotiation).
• No MAC at Chart severe enough to give Baker Hughes a walk-away right.
• Falsification test (bull): an 8-K disclosing an EU Phase II opening, a remedy demand, a financing problem, or a MAC assertion would break the “clean close” thesis and widen the spread sharply.

For the bear case (deal breaks; stock reverts):

• One of the above conditions fails — most plausibly an EU remedy/Phase II outcome — and the parties cannot cure it before the outside date.
• Chart reverts to standalone value (~$145–$175) on its fundamentals, cushioned by the $500M reverse break fee.
• Falsification test (bear): EU clearance and a definitive closing announcement would falsify the bear case entirely — at which point the equity simply pays $210 and ceases to exist as a public security.

The crux. Unusually for an equity, the bull and bear cases turn on a single binary regulatory event (EU clearance) rather than on business performance, valuation, or competitive dynamics. Everything in Sections 1–8 describes the asset Baker Hughes is buying and the value a holder would fall back on if the deal failed — but the price is governed almost entirely by deal completion. That is why this memo’s honest conclusion is that there is no fundamental edge here: the analysis is essentially complete, and the deal very nearly so.

15. Source Appendix

See Appendix B (Source Appendix) below for the full source list with URLs and access dates. Primary sources: Chart Industries SEC filings (8-K of 7/29/25 announcing the Baker Hughes agreement; 8-K of 6/4/25 on the Flowserve MOE; DEFM14A merger proxy; FY2025 results 8-K/press release of 2/27/26; 10-K); Baker Hughes SEC filings and press releases; HSR/SAMR/EU regulatory disclosures (via 8-K summaries, MLex, TipRanks); ROIC.ai financial data (income statement, balance sheet, cash flow, profitability, per-share, enterprise value, company profile); AZI valuation-percentile and price-history data; FactorsToday factor/positioning data; and reputable trade/financial press (JPT, OilPrice, MDM, StockTitan, Investing.com). Management commentary (earnings releases, deal rationale) is treated as hypothesis and validated against filings and market data against primary sources.

The body of this article (Sections 1–15) deliberately contains no buy/sell recommendation and no price target; valuation is discussed only as embedded expectations and scenarios. The sole exception is the clearly-labeled “Claude’s Take” block at the top, which is the author’s own independent opinion and general information only — not investment advice.

APPENDIX A — Standard Diligence Questionnaire — Chart Industries, Inc. (NYSE: GTLS)

Supplemental to the article. Fact / Interpretation / Assumption labeled where it matters. Context that dominates every answer: GTLS is a pending all-cash acquisition by Baker Hughes at $210.00/share (announced 29-Jul-2025, expected close Q2-2026); the equity trades at ~$208, a ~1% spread.

General

What thoughtful questions have other investors asked about this company? Almost all current investor attention is on the merger arbitrage, not the fundamentals: (1) Will the EU antitrust review (Phase I filed May-2026) clear cleanly and on time? (2) What is the annualized return on the ~1% spread given the expected close, and is it adequate for the residual break risk? (3) What is Chart’s standalone value if the deal breaks (the downside anchor)? (4) Was $210 a “full” or “generous” price — i.e., did Baker Hughes overpay for the synergies and aftermarket annuity? Pre-deal, the durable fundamental debates were: (a) whether the Howden acquisition’s margin gains justified the leverage and ~6–7% ROIC; (b) the durability of LNG/data-center order momentum vs. the cyclicality of industrial-gas tanks; and © whether the hydrogen/CCUS Specialty optionality would ever convert.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Margins are at a structural high (post-Howden mix shift; gross margin ~33.7%, EBITDA ~21.2%), while organic volume is mid-cycle with pockets of softness (industrial-gas/CTS −2.1% in FY25). Backlog (1.33 book-to-bill, $5.9B) suggests the order cycle is healthy-to-rising. Not an obvious cyclical peak in volume; arguably a peak in margin. Driven by external environment or internal actions? Both — internal (Howden synergies, mix, pricing discipline drove the margin expansion) and external (LNG FID cycle, industrial production, data-center build drive volume). How stable are revenues? Moderately — ~31% (RSL) is recurring aftermarket and stable; the rest (HTS, CTS, Specialty) is project/equipment-driven and lumpy. Backlog provides ~12-month visibility. Outlook for products/services? Secular tailwinds (LNG, industrial gas, data-center cooling, energy transition) layered over genuine cyclicality and FID-timing lumpiness. How big will this market be? Growing — LNG and data-center thermal management are multi-year growth markets; industrial gas grows with GDP/industrial output; hydrogen/CCUS is large-but-policy-dependent. Global.

Business Quality & Competitive Moat

More or less competitive industry? Fragmented and segment-specific; consolidating in heat transfer/aftermarket (Chart itself a consolidator via Howden). No single dominant competitor across segments. How profitable (ROIC, ROE)? Fact: Segment adjusted operating margins are high (RSL 32.6%, HTS 30.1%) but company ROIC is only ~6–7% (around WACC) because of the expensive, intangible-heavy Howden balance sheet. ROE is distorted by negative tangible equity. How profitable is the industry / barriers to entry? Moderate barriers — cryogenic engineering, safety qualification, reference installations, aftermarket installed base. Real but not a structural monopoly. Can the business be easily understood? Yes — it makes and services cryogenic/process equipment. The capital structure and GAAP-vs-adjusted earnings are the complex part. Undermined by foreign low-cost labor? Partially in commoditized tanks (CTS); much less in engineered heat-transfer and aftermarket where qualification and proximity matter. Do brands matter? Modestly — engineering reputation and reference installations matter more than consumer-style brand. Nature of competition? Engineering capability, lead-time, breadth (“full molecule”), installed base, price (especially in tanks). Customer switching costs? Real in the aftermarket (the OEM that built the equipment is the natural servicer — qualification/warranty/downtime lock-in); low in commodity tanks.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The installed-base aftermarket annuity and engineering IP are economically valuable but not separately carried; conversely the balance sheet is heavy with acquired intangibles. Off-balance-sheet liabilities? Standard operating leases, performance guarantees, and warranty obligations; nothing flagged as unusual. A mandatory-convertible preferred sits in the capital structure (source of ~$27.2M preferred dividend). How conservative is the accounting? Mixed — large adjusting items between GAAP ($0.30 EPS) and adjusted ($9.72 EPS) require care; intangible amortization and mark-to-market noise are real. Treat adjusted figures skeptically and reconcile to cash. How CapEx-hungry? Moderate (~$92–128M/yr, ~2–3% of sales) — but working-capital-hungry: FY25 OCF ($292.7M) lagged on a $221.6M receivables/contract-asset build as backlog converts. FCF conversion of adjusted earnings is poor.

Capital Allocation & Management

How much FCF, and how used? FY25 FCF $204.8M (FY24 ~$375M); used primarily to deleverage (net debt $3.65B→$3.2B) and fund a small preferred/dividend. No buybacks post-Howden (balance sheet couldn’t support them). Philosophy? Growth-via-transformational-M&A (Howden), then deleverage, then — ultimately — sell the company for cash. Significant acquisitions? The $4.4B Howden acquisition (closed Mar-2023) is the defining capital decision — strategically sound, financially aggressive, ROIC-dilutive near-term. And then Chart itself became the acquired. Buying back shares? No (count drifted up with Howden financing/convertibles). Issuing shares to insiders? Standard equity comp; no unusual insider issuance flagged. In a change-of-control, management equity vests/cashes out. Compensation policy? Conventional industrial mix; generic demerit of no strong returns-on-capital metric. Largely moot given the pending cash exit. Motivations of management? The board’s willingness to switch from the friendly Flowserve all-stock MOE to Baker Hughes’ superior all-cash $210 bid — rather than entrench — is a positive governance signal; it prioritized shareholder value (certain cash) over deal-protection.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — ordinary U.S. common stock (NYSE), no K-1. Dividend policy? Minimal common dividend (~$0.60/share, effectively the preferred coupon); not an income story. Dividend irrelevant in a cash takeover. How profitable? High segment margins, modest ~6–7% ROIC; adjusted EPS $9.72 vs. reported $0.30. Net income diverging from cash from operations? Yes, and importantly: adjusted earnings (~$440M) are not fully cash-backed (FY25 FCF $204.8M) due to working-capital intensity and the capital structure. A key quality-of-earnings caution.

Risks & Downside

What would cause the stock to decline? Essentially one thing now: the Baker Hughes deal breaking or being materially delayed/repriced (EU antitrust the swing factor; financing/MAC the tail). A break would send the stock to ~$145–$175 standalone (−20% to −30%). Risk of catastrophic loss? Low from $208 — the realistic bad case is a ~25% reversion to standalone value, cushioned by a $500M reverse break fee and a ~$200M+ FCF business; not a wipeout. Chance of total loss? Negligible.

Recent News & Events

Has the business environment changed recently? Transformationally — Chart agreed to be acquired (Flowserve MOE 6/4/25, superseded by Baker Hughes all-cash $210 on 7/29/25). Regulatory clearances followed (HSR Nov-2025; China SAMR unconditional Nov-2025; EU Phase I filed May-2026). Expected close Q2-2026. Significant acquisitions? Chart is the target; the relevant prior deal is Howden (2023). Change in accounting policies? None flagged beyond purchase-accounting effects of Howden. Recent changes — markets, facilities, management? Continued push into data-center cooling and LNG; CEO transition during the deal period (subordinate to closing). Operationally: +703 new customers in 2025, +29% Uptime connections, +21% assets under service.

APPENDIX B — Source Appendix — Chart Industries, Inc. (NYSE: GTLS)

Report date: 2026-06-21. Primary sources prioritized. Management commentary treated as hypothesis and validated against filings and market data. Access dates 2026-06-21 unless noted.

A. Primary — SEC filings & company disclosures (Chart Industries, CIK 0000892553)

1. Form 8-K, 29-Jul-2025 — announcement of definitive agreement for Baker Hughes to acquire Chart for $210.00/share cash. https://www.sec.gov/Archives/edgar/data/892553/000119312525167126/d89051d8k.htm and exhibit https://www.sec.gov/Archives/edgar/data/0000892553/000119312525167126/d89051dex992.htm
2. Form 8-K, 4-Jun-2025 — prior all-stock merger-of-equals agreement with Flowserve (subsequently terminated). https://www.sec.gov/Archives/edgar/data/892553/000119312525134450/d847684d8k.htm
3. DEFM14A — merger proxy statement (deal terms, $210/share, outside date 28-Jul-2026 auto-extending to 28-Jul-2027, termination fees $250M / $500M reverse). (Chart Industries merger proxy.)
4. Form 8-K, 27-Feb-2026 — Q4 & Full-Year 2025 results. Press release (GlobeNewswire): https://www.globenewswire.com/news-release/2026/02/27/3246815/9318/en/Chart-Industries-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html ; SEC: https://www.sec.gov/Archives/edgar/data/892553/000089255326000025/gtls-20260227.htm
5. Form 8-K, 7-Nov-2025 — HSR waiting-period expiration (6-Nov-2025). https://www.sec.gov/Archives/edgar/data/892553/000119312525270810/d93917d8k.htm
6. Form 8-K, 17-Nov-2025 / Dec-2025 — regulatory updates (incl. China SAMR clearance period). https://www.sec.gov/Archives/edgar/data/892553/000119312525283999/d76003d8k.htm
7. Form 8-K, 21-May-2026 — merger/regulatory timeline update (EU Form CO / Phase I). https://www.sec.gov/Archives/edgar/data/0000892553/000119312526234381/d13051d8k.htm
8. Form 8-K, 15-Jun-2026 — material event / timeline update. https://www.sec.gov/Archives/edgar/data/892553/000119312526271052/d79888d8k.htm
9. Chart Industries FY2025 Form 10-K and prior 10-Ks / 10-Qs — financial statements, segment data, risk factors. (EDGAR, CIK 0000892553.)
10. FY2024 results 8-K (28-Feb-2025) and earlier results releases. https://www.sec.gov/Archives/edgar/data/0000892553/000089255325000036/exhibit991gtls-20241231pre.htm

B. Primary — Acquirer (Baker Hughes, CIK 0001701605)

11. Baker Hughes 8-K, 29-Jul-2025 — acquisition announcement and rationale ($13.6B EV, ~$325M synergies). https://www.sec.gov/Archives/edgar/data/1701605/000119312525167118/d912206d8k.htm and exhibit https://www.sec.gov/Archives/edgar/data/0001701605/000119312525167118/d912206dex991.htm
12. Baker Hughes 8-K (2026) — regulatory/HSR update. https://www.sec.gov/Archives/edgar/data/0001701605/000119312526085437/d57122dex991.htm
13. Baker Hughes 424B2 (2026) — euro-denominated senior notes issued to fund the Chart acquisition. https://www.sec.gov/Archives/edgar/data/1701605/000119312526089950/d120546d424b2.htm
14. Baker Hughes 10-Q (FY2026) — merger disclosure. https://www.sec.gov/Archives/edgar/data/0001701605/000170160526000014/bkr-20260331.htm

C. Quantitative data services

15. ROIC.ai — company profile; income statement (FY2020–2025); balance sheet; cash flow; profitability ratios; per-share data; enterprise value; latest stock price. Third-party aggregated; reconciled to filings.
16. AZI / azitrading.com — valuation_index own-history percentiles (composite 68.3; P/B 73.2; P/S 63.4; P/E null on negative TTM GAAP EPS) and 5-year daily price CSV (OHLCV, EMAs, beta).
17. FactorsToday (factorstoday.com/api) — stock loadings (trailing market beta ~1.48–1.52; R² ~0.43), leaderboard (y1 return +44%, 6-month realized vol ~2.3%, max drawdown −0.9% — deal-pinned), stock-info, related-stocks (matched to low-vol/momentum ETF baskets, not industrial peers — a positioning artifact of the merger pin).

D. Regulatory & trade press (secondary, for deal-status corroboration)

18. JPT (Journal of Petroleum Technology): “Baker Hughes Buys Chart Industries in $13.6 Billion Deal.” https://jpt.spe.org/baker-hughes-buys-chart-industries-in-13-6-billion-deal
19. OilPrice.com: “Baker Hughes Wins Shareholder Nod for $13.6 B Chart Industries Takeover.” https://oilprice.com/Latest-Energy-News/World-News/Baker-Hughes-Wins-Shareholder-Nod-for-136-B-Chart-Industries-Takeover.html
20. MLex: “Baker Hughes–Chart Industries among deals unconditionally cleared in China Nov. 24–30.” https://www.mlex.com/mlex/articles/2418552/baker-hughes-chart-industries-among-deals-unconditionally-cleared-in-china-nov-24-30
21. Investing.com: “Chart Industries and Baker Hughes merger clears HSR Act waiting period.” https://www.investing.com/news/sec-filings/chart-industries-and-baker-hughes-merger-clears-hsr-act-waiting-period-93CH-4341714
22. TipRanks / Globe and Mail: “Chart Industries Advances Baker Hughes Acquisition with EU Review.” https://www.tipranks.com/news/company-announcements/chart-industries-advances-baker-hughes-acquisition-with-eu-review
23. StockTitan: GTLS/BKR 8-K summaries (merger timeline, HSR clearance, mid-2026 close). https://www.stocktitan.net/sec-filings/GTLS/ and https://www.stocktitan.net/sec-filings/BKR/
24. Modern Distribution Management: “Baker Hughes Buying Chart Industries in $13.6B Deal.” https://www.mdm.com/news/operations/manufacturing/baker-hughes-buying-chart-industries-in-13-6b-deal/
25. Panabee: deal terms / synergy and regulatory-progress summaries. https://www.panabee.com/news/

E. Notes on data treatment

• Authority/reconciliation: SEC filings are primary and authoritative for US-filer financials; ROIC.ai, AZI, and FactorsToday are third-party aggregated data used to accelerate and cross-check, reconciled to filings. Where a discrepancy would be material, the filing governs.
• GAAP vs. adjusted: FY2025 reported diluted EPS ($0.30) and adjusted diluted EPS ($9.72) diverge sharply due to Howden intangible amortization, interest expense, mark-to-market items, and preferred dividends; both are reported with the caveat that owner-earnings sit between them and that FCF ($204.8M) does not fully back adjusted earnings.
• Price/positioning context: the equity price is governed by the pending cash merger, not by fundamentals; valuation percentiles and factor loadings are reported as context only and are not used cross-sectionally.